Emmanuel Oga

Dr. Emmanuel Oga

RTI International, Research Triangle Park, NC 27709, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Cancer Epidemiology
Verified
Journal Article
Closed access
EJElima Jedy-Agba
Elima Jedy-Agba
MCMaria Paula Curado
Maria Paula Curado
OOOlufemi Ogunbiyi
Olufemi Ogunbiyi
EOEmmanuel Oga
Emmanuel Oga
TFToyin Fabowale
Toyin Fabowale
CAClement A. Adebamowo
Clement A. Adebamowo

24 March 2018 in Addiction
Verified
Journal Article
Closed access
PDF file
BJBrantley P. Jarvis
Brantley P. Jarvis
AHAugust F. Holtyn
August F. Holtyn
SSShrinidhi Subramaniam
Shrinidhi Subramaniam
DTD. Andrew Tompkins
D. Andrew Tompkins
EOEmmanuel Oga
Emmanuel Oga
KSKenneth Silverman
Kenneth Silverman

20 January 2016 in Journal of Obesity
Verified
Journal Article
Open access
PDF file
EOEmmanuel Oga
Emmanuel Oga
OEOlabimpe Ruth Eseyin
Olabimpe Ruth Eseyin
There is scientific consensus that obesity increases the risk of cardiovascular diseases, including heart failure. However, among persons who already have heart failure, outcomes seem to be better in obese persons as compared with lean persons: this has been termed theobesity paradox, the mechanisms of which remain unclear. This study systematically reviewed the evidence of the relationship between heart failure mortality (and survival) and weight status. Search of the PubMed/MEDLINE and EMBASE databases was done according to the PRISMA protocol. The initial search identified 9879 potentially relevant papers, out of which ten studies met the inclusion criteria. One study was a randomized clinical trial and 9 were observational cohort studies: 6 prospective and 3 retrospective studies. All studies used the BMI, WC, or TSF as measure of body fatness and NYHA Classification of Heart Failure and had single outcomes, death, as study endpoint. All studies included in review were longitudinal studies. All ten studies reported improved outcomes for obese heart failure patients as compared with their normal weight counterparts; worse prognosis was demonstrated for extreme obesity (BMI>40 kg/m2). The findings of this review will be of significance in informing the practice of asking obese persons with heart failure to lose weight. However, any such recommendation on weight loss must be consequent upon more conclusive evidence on the mechanisms of the obesity paradox in heart failure and exclusion of collider bias.

1 May 2019 in Obstetrics & Gynecology
Verified
Journal Article
Open access
VCVictoria H. Coleman-Cowger
Victoria H. Coleman-Cowger
EOEmmanuel Oga
Emmanuel Oga
EPErica N. Peters
Erica N. Peters
KTKathleen E. Trocin
Kathleen E. Trocin
BKBartosz Koszowski
Bartosz Koszowski
KMKatrina Mark
Katrina Mark
OBJECTIVE: To compare and evaluate the accuracy of three screening tools in identifying illicit drug use and prescription drug misuse among a diverse sample of pregnant women. METHODS: This prospective cross-sectional study enrolled a consecutive sample of 500 pregnant women, stratified by trimester, receiving care in two prenatal clinical settings in Baltimore, Maryland, from January 2017 to January 2018. All participants were administered three index tests: 4P's Plus, NIDA Quick Screen-ASSIST (Modified Alcohol, Smoking and Substance Involvement Screening Test), and the SURP-P (Substance Use Risk Profile-Pregnancy) scale, and administered reference tests (urine and hair drug testing) at the in-person baseline visit. To assess test–retest reliability of the index tests, screening tool administrations were repeated 1 week later by telephone. For each screening tool, sensitivity, specificity, positive predictive value, negative predictive value and test–retest reliability were computed. Results were stratified by age, race, and trimester of pregnancy. RESULTS: Of the 500 enrolled pregnant women, 494 completed the index screening tools, 497 completed reference testing, and 453 underwent test–retest analysis. For the 4P's Plus, sensitivity=90.2% (84.5, 93.8), and specificity=29.6% (24.4, 35.2). For the NIDA Quick Screen-ASSIST, sensitivity=79.7% (71.2, 84.2), and specificity=82.8% (78.1, 87.1). For the SURP-P, sensitivity=92.4% (87.6, 95.8) and specificity=21.8% (17.4, 27.2). Test–retest reliability (phi correlation coefficients) was 0.84, 0.77, and 0.79 for the 4P's Plus, NIDA Quick Screen-ASSIST and the SURP-P, respectively. For all screening tools, there were differences in validity indices by age and race, but no differences by trimester. CONCLUSION: The SURP-P and 4P's Plus had high sensitivity and negative predictive values, making them more ideal screening tests than the NIDA Quick Screen-ASSIST. A clear recommendation for a clinically useful screening tool for prenatal substance use is crucial to allow for prompt and appropriate follow-up and intervention.

1 July 2018 in Neurotoxicology and Teratology
Verified
Journal Article
Closed access
VCVictoria H. Coleman-Cowger
Victoria H. Coleman-Cowger
EOEmmanuel Oga
Emmanuel Oga
EPErica N. Peters
Erica N. Peters
KMKatrina Mark
Katrina Mark

1 October 2012 in Cancer Epidemiology
Verified
Journal Article
Closed access
EJElima E. Jedy-Agba
Elima E. Jedy-Agba
MCMaria Paula Curado
Maria Paula Curado
EOEmmanuel Oga
Emmanuel Oga
MSModupeola O. Samaila
Modupeola O. Samaila
EEEmmanuel R. Ezeome
Emmanuel R. Ezeome
CAClement A. Adebamowo
Clement A. Adebamowo